创业慧康：订单增长为成长护航，CTasy启动市场推广

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook based on the anticipated growth in orders and revenue recovery [5]. Core Insights - The company has successfully secured 29 software orders exceeding 10 million yuan in 2023, totaling nearly 500 million yuan, primarily in the smart hospital and public health sectors [3]. - In Q1 2024, the company reported a revenue of 375 million yuan, a year-on-year increase of 7.76%, and a net profit attributable to shareholders of 12 million yuan, up 19.03% year-on-year, suggesting a positive trend in performance recovery [3][5]. - The overall demand for medical IT is expected to improve, benefiting the company's growth trajectory [5]. Financial Summary - For 2023, the company achieved a revenue of 1.616 billion yuan, representing a year-on-year growth of 5.81%, while the net profit attributable to shareholders was 37 million yuan, down 13.93% [4]. - Projections for 2024 estimate revenues of 1.894 billion yuan, reflecting a growth of 17.2%, and a significant increase in net profit to 203 million yuan, a growth of 453.5% [4]. - The gross margin is expected to improve from 47.0% in 2023 to 48.6% in 2024, indicating enhanced profitability [4].